Psoriasis treatment and biologic switching: The association with clinical characteristics and laboratory biomarkers over a 13‐year retrospective study
The Journal of Dermatology · 2024
DOI: 10.1111/1346-8138.17465 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Asumi Koyama und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Psoriasis, Biomarkers, Biological Products, Severity of Illness Index. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The advent of biologics has greatly improved patient outcomes, yet some patients are compelled to switch therapies. Predicting these therapeutic failures is important; however, the factors associated with switching biologics have not been fully explored. This study examined patterns and determinants of biologics switching in psoriasis treatment retrospectively over 13 years. We focused on the association between clinical characteristics, basal laboratory data, and frequency of biologics switching. The findings revealed that elevated Psoriasis Area Severity Index scores and the presence of arthritis were observed in patients who experienced two or more treatment switches compared with those without treatment switches. Moreover, neutrophil to lymphocyte ratio was associated with higher biologics switching rates, indicating that systemic inflammation significantly impacts treatment adherence. A treatment approach, taking into account both the clinical presentation and inflammatory biomarkers, may be important for optimizing patient management in psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Division for Health Service Promotion, University of Tokyo, Tokyo, Japan.
- Immune-Mediated Diseases Therapy Center, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
ORCID-Profile: Sayaka Shibata
Zitieren
APA
Koyama, A., Li, L., Yamamoto, T., Taira, H., Sugimoto, E., Ito, Y., Mizuno, Y., Awaji, K., Tateishi, S., Kanda, H., Sato, S., & Shibata, S. (2024). Psoriasis treatment and biologic switching: The association with clinical characteristics and laboratory biomarkers over a 13‐year retrospective study. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17465
Vancouver
Koyama A, Li L, Yamamoto T, Taira H, Sugimoto E, Ito Y, et al. Psoriasis treatment and biologic switching: The association with clinical characteristics and laboratory biomarkers over a 13‐year retrospective study. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17465
BibTeX
@article{Koyama2024,
author = {Koyama, Asumi and Li, Lixin and Yamamoto, Toyoki and Taira, Haruka and Sugimoto, Eiki and Ito, Yukiko and Mizuno, Yuka and Awaji, Kentaro and Tateishi, Shoko and Kanda, Hiroko and Sato, Shinichi and Shibata, Sayaka},
title = {Psoriasis treatment and biologic switching: The association with clinical characteristics and laboratory biomarkers over a 13‐year retrospective study},
journal = {The Journal of Dermatology},
year = {2024},
doi = {10.1111/1346-8138.17465}
}
EUVIMED